Skip to main content
Top
Published in: Breast Cancer Research 4/2012

01-08-2012 | Editorial

Is breast cancer a part of Lynch syndrome?

Author: James M Ford

Published in: Breast Cancer Research | Issue 4/2012

Login to get access

Abstract

A long-standing question is whether breast cancer is an integral part of Lynch syndrome, also known as hereditary non-polyposis colorectal cancer. A recent study by Lotsari and colleagues analyzes molecular features of breast cancers from families with Lynch syndrome, including germline mutation carriers and their non-mutation carrier siblings, and controls with sporadic breast cancer. The study finds microsatellite instability and loss of mismatch DNA repair protein expression in one third and two thirds of Lynch syndrome samples, respectively, but in none of the non-mutation carriers or controls. Overall, the age of diagnosis of breast cancer in Lynch syndrome mutation carriers is no different than that in non-carriers, but diagnosis age was lower in those carriers whose breast tumors exhibited defects in mismatch repair. These results have important implications for genetic counseling and genetic testing of families with breast cancer and other tumors associated with Lynch syndrome, such as colorectal and endometrial cancers.
Literature
1.
go back to reference Lotsari JE, Gylling A, Abdel-Rahman WM, Nieminen TT, Aittomaki K, Friman M, Pitkanen R, Aarnio M, Jarvinen HJ, Mecklin JP, Kuopio T, Peltomaki P: Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res. 2012, 14: R90-10.1186/bcr3205.CrossRefPubMedPubMedCentral Lotsari JE, Gylling A, Abdel-Rahman WM, Nieminen TT, Aittomaki K, Friman M, Pitkanen R, Aarnio M, Jarvinen HJ, Mecklin JP, Kuopio T, Peltomaki P: Breast carcinoma and Lynch syndrome: molecular analysis of tumors arising in mutation carriers, non-carriers, and sporadic cases. Breast Cancer Res. 2012, 14: R90-10.1186/bcr3205.CrossRefPubMedPubMedCentral
2.
go back to reference Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144: 646-674. 10.1016/j.cell.2011.02.013.CrossRefPubMed
3.
go back to reference Bodmer W, Bielas JH, Beckman RA: Genetic instability is not a requirement for tumor development. Cancer Res. 2008, 68: 3558-3560. 10.1158/0008-5472.CAN-07-6544.CrossRefPubMedPubMedCentral Bodmer W, Bielas JH, Beckman RA: Genetic instability is not a requirement for tumor development. Cancer Res. 2008, 68: 3558-3560. 10.1158/0008-5472.CAN-07-6544.CrossRefPubMedPubMedCentral
4.
go back to reference Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008, 68: 3551-3557. 10.1158/0008-5472.CAN-07-5835.CrossRefPubMed Loeb LA, Bielas JH, Beckman RA: Cancers exhibit a mutator phenotype: clinical implications. Cancer Res. 2008, 68: 3551-3557. 10.1158/0008-5472.CAN-07-5835.CrossRefPubMed
5.
go back to reference Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 2003, 348: 919-932. 10.1056/NEJMra012242.CrossRefPubMed Lynch HT, de la Chapelle A: Hereditary colorectal cancer. N Engl J Med. 2003, 348: 919-932. 10.1056/NEJMra012242.CrossRefPubMed
6.
go back to reference Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008, 26: 5783-5788. 10.1200/JCO.2008.17.5950.CrossRefPubMedPubMedCentral Hampel H, Frankel WL, Martin E, Arnold M, Khanduja K, Kuebler P, Clendenning M, Sotamaa K, Prior T, Westman JA, Panescu J, Fix D, Lockman J, LaJeunesse J, Comeras I, de la Chapelle A: Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008, 26: 5783-5788. 10.1200/JCO.2008.17.5950.CrossRefPubMedPubMedCentral
7.
go back to reference Ford JM, Whittemore AS: Predicting and preventing hereditary colorectal cancer. JAMA. 2006, 296: 1521-1523. 10.1001/jama.296.12.1521.CrossRefPubMed Ford JM, Whittemore AS: Predicting and preventing hereditary colorectal cancer. JAMA. 2006, 296: 1521-1523. 10.1001/jama.296.12.1521.CrossRefPubMed
8.
go back to reference Lynch HT, Watson P, Kriegler M, Lynch JF, Lanspa SJ, Marcus J, Smyrk T, Fitzgibbons RJ, Cristofaro G: Differential diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome I and Lynch syndrome II). Dis Colon Rectum. 1988, 31: 372-377. 10.1007/BF02564888.CrossRefPubMed Lynch HT, Watson P, Kriegler M, Lynch JF, Lanspa SJ, Marcus J, Smyrk T, Fitzgibbons RJ, Cristofaro G: Differential diagnosis of hereditary nonpolyposis colorectal cancer (Lynch syndrome I and Lynch syndrome II). Dis Colon Rectum. 1988, 31: 372-377. 10.1007/BF02564888.CrossRefPubMed
9.
go back to reference Vasen HF, Morreau H, Nortier JW: Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?. Am J Hum Genet. 2001, 68: 1533-1535. 10.1086/320610.CrossRefPubMedPubMedCentral Vasen HF, Morreau H, Nortier JW: Is breast cancer part of the tumor spectrum of hereditary nonpolyposis colorectal cancer?. Am J Hum Genet. 2001, 68: 1533-1535. 10.1086/320610.CrossRefPubMedPubMedCentral
10.
go back to reference Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004, 96: 261-268. 10.1093/jnci/djh034.CrossRefPubMedPubMedCentral Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S: Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst. 2004, 96: 261-268. 10.1093/jnci/djh034.CrossRefPubMedPubMedCentral
11.
go back to reference Adem C, Soderberg CL, Cunningham JM, Reynolds C, Sebo TJ, Thibodeau SN, Hartmann LC, Jenkins RB: Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer. 2003, 107: 580-582. 10.1002/ijc.11442.CrossRefPubMed Adem C, Soderberg CL, Cunningham JM, Reynolds C, Sebo TJ, Thibodeau SN, Hartmann LC, Jenkins RB: Microsatellite instability in hereditary and sporadic breast cancers. Int J Cancer. 2003, 107: 580-582. 10.1002/ijc.11442.CrossRefPubMed
12.
go back to reference Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H, Heinimann K: Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer. 2012, 51: 83-91. 10.1002/gcc.20935.CrossRefPubMed Buerki N, Gautier L, Kovac M, Marra G, Buser M, Mueller H, Heinimann K: Evidence for breast cancer as an integral part of Lynch syndrome. Genes Chromosomes Cancer. 2012, 51: 83-91. 10.1002/gcc.20935.CrossRefPubMed
13.
go back to reference Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le Marchand L, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP: Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res. 2010, 16: 2214-2224. 10.1158/1078-0432.CCR-09-3058.CrossRefPubMedPubMedCentral Walsh MD, Buchanan DD, Cummings MC, Pearson SA, Arnold ST, Clendenning M, Walters R, McKeone DM, Spurdle AB, Hopper JL, Jenkins MA, Phillips KD, Suthers GK, George J, Goldblatt J, Muir A, Tucker K, Pelzer E, Gattas MR, Woodall S, Parry S, Macrae FA, Haile RW, Baron JA, Potter JD, Le Marchand L, Bapat B, Thibodeau SN, Lindor NM, McGuckin MA, Young JP: Lynch syndrome-associated breast cancers: clinicopathologic characteristics of a case series from the colon cancer family registry. Clin Cancer Res. 2010, 16: 2214-2224. 10.1158/1078-0432.CCR-09-3058.CrossRefPubMedPubMedCentral
14.
go back to reference Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, Macrae FA, Goldblatt J, Southey MC, Arnold J, Thibodeau SN, Gunawardena SR, Bapat B, Baron JA, Casey G, Gallinger S, Le Marchand L, Newcomb PA, Haile RW, Hopper JL, Jenkins MA: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012, 30: 958-964. 10.1200/JCO.2011.39.5590.CrossRefPubMedPubMedCentral Win AK, Young JP, Lindor NM, Tucker KM, Ahnen DJ, Young GP, Buchanan DD, Clendenning M, Giles GG, Winship I, Macrae FA, Goldblatt J, Southey MC, Arnold J, Thibodeau SN, Gunawardena SR, Bapat B, Baron JA, Casey G, Gallinger S, Le Marchand L, Newcomb PA, Haile RW, Hopper JL, Jenkins MA: Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study. J Clin Oncol. 2012, 30: 958-964. 10.1200/JCO.2011.39.5590.CrossRefPubMedPubMedCentral
15.
go back to reference Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA: Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011, 155: 69-79.CrossRefPubMedPubMedCentral Ladabaum U, Wang G, Terdiman J, Blanco A, Kuppermann M, Boland CR, Ford J, Elkin E, Phillips KA: Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis. Ann Intern Med. 2011, 155: 69-79.CrossRefPubMedPubMedCentral
Metadata
Title
Is breast cancer a part of Lynch syndrome?
Author
James M Ford
Publication date
01-08-2012
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2012
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3241

Other articles of this Issue 4/2012

Breast Cancer Research 4/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine